100 related articles for article (PubMed ID: 24021940)
1. Application of the Bethesda System for Reporting Thyroid Cytopathology in the Eastern Province of Saudi Arabia: phase I pilot retrospective analysis.
Al-Abbadi MA; Shareef SQ; Ali JA; Yousef MM
Acta Cytol; 2013; 57(5):481-8. PubMed ID: 24021940
[TBL] [Abstract][Full Text] [Related]
2. Yield of repeat fine-needle aspiration biopsy and rate of malignancy in patients with atypia or follicular lesion of undetermined significance: the impact of the Bethesda System for Reporting Thyroid Cytopathology.
Chen JC; Pace SC; Chen BA; Khiyami A; McHenry CR
Surgery; 2012 Dec; 152(6):1037-44. PubMed ID: 23040711
[TBL] [Abstract][Full Text] [Related]
3. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
[No Abstract] [Full Text] [Related]
4. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System.
Sullivan PS; Hirschowitz SL; Fung PC; Apple SK
Cancer Cytopathol; 2014 Dec; 122(12):866-72. PubMed ID: 25078420
[TBL] [Abstract][Full Text] [Related]
5. Application of the Bethesda System for Reporting Thyroid Cytopathology in the Eastern Province of Saudi Arabia: A Follow-Up Study.
Alabdulqader NA; Shareef SQ; Ali JA; Yousef MM; Al-Abbadi MA
Acta Cytol; 2015; 59(3):233-8. PubMed ID: 26044567
[TBL] [Abstract][Full Text] [Related]
6. The impact of implementation of the Bethesda System for Reporting Thyroid Cytopathology on the surgical treatment of thyroid nodules.
Richmond BK; O'Brien BA; Mangano W; Thompson S; Kemper S
Am Surg; 2012 Jun; 78(6):706-10. PubMed ID: 22643269
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the bethesda system for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes.
Wong LQ; Baloch ZW
Adv Anat Pathol; 2012 Sep; 19(5):313-9. PubMed ID: 22885380
[TBL] [Abstract][Full Text] [Related]
8. Implementation of the bethesda system for reporting thyroid cytopathology: interobserver concordance and reclassification of previously inconclusive aspirates.
Pathak P; Srivastava R; Singh N; Arora VK; Bhatia A
Diagn Cytopathol; 2014 Nov; 42(11):944-9. PubMed ID: 24692395
[TBL] [Abstract][Full Text] [Related]
9. Application of the Bethesda Classification for Thyroid Fine-Needle Aspiration: Institutional Experience and Meta-analysis.
Krauss EA; Mahon M; Fede JM; Zhang L
Arch Pathol Lab Med; 2016 Oct; 140(10):1121-31. PubMed ID: 27684984
[TBL] [Abstract][Full Text] [Related]
10. Reclassifying formerly indeterminate thyroid FNAs using the Bethesda system reduces the number of inconclusive cases.
Song JY; Chu YC; Kim L; Park IS; Han JY; Kim JM
Acta Cytol; 2012; 56(2):122-9. PubMed ID: 22378073
[TBL] [Abstract][Full Text] [Related]
11. A tertiary center's experience with second review of 3885 thyroid cytopathology specimens.
Olson MT; Boonyaarunnate T; Aragon Han P; Umbricht CB; Ali SZ; Zeiger MA
J Clin Endocrinol Metab; 2013 Apr; 98(4):1450-7. PubMed ID: 23436916
[TBL] [Abstract][Full Text] [Related]
12. Consistency in the Distribution of Bethesda System for Reporting Thyroid Cytology Categories Over 9 Years: A Single Institute, Retrospective Study.
Harris M; Zloczower E; Pinhas S; Allon R; Zornitzki T; Malka L; Cohen Y; Lahav Y; Cohen O
Endocr Pract; 2024 Jun; 30(6):546-550. PubMed ID: 38570016
[TBL] [Abstract][Full Text] [Related]
13. Adequacy criteria for thyroid FNA evaluated by ThinPrep slides only.
Vivero M; Renshaw AA; Krane JF
Cancer Cytopathol; 2017 Jul; 125(7):534-543. PubMed ID: 28388017
[TBL] [Abstract][Full Text] [Related]
14. Correlation of thyroid fine-needle aspiration with final histopathology: a case series.
Gürkan Dumlu E; Kiyak G; Bozkurt B; Tokaç M; Polat B; Cakir B; Güler G; Kiliç M
Minerva Chir; 2013 Apr; 68(2):191-7. PubMed ID: 23612233
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of the Bethesda system for reporting thyroid cytopathology: Real-life experience.
Avior G; Dagan O; Shochat I; Frenkel Y; Tessler I; Meir A; Jaffe A; Cohen O
Clin Endocrinol (Oxf); 2021 Mar; 94(3):521-527. PubMed ID: 32981060
[TBL] [Abstract][Full Text] [Related]
16. Thyroid fine-needle aspiration reporting rates and outcomes before and after Bethesda implementation within a combined academic and community hospital system.
Harvey AM; Mody DR; Amrikachi M
Arch Pathol Lab Med; 2013 Nov; 137(11):1664-8. PubMed ID: 24168507
[TBL] [Abstract][Full Text] [Related]
17. 'Suspicious for a follicular neoplasm' before and after the Bethesda System for Reporting Thyroid Cytopathology: impact of standardized terminology.
Boonyaarunnate T; Olson MT; Ali SZ
Acta Cytol; 2013; 57(5):455-63. PubMed ID: 24021843
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Bethesda System and the ACR TIRADS in an Endemic Goiter Region.
Karaagac M; Sarigoz T; Ertan T; Topuz O
Endocr Res; 2020 Nov; 45(4):226-232. PubMed ID: 32729365
[TBL] [Abstract][Full Text] [Related]
19. The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy.
Wu HH; Rose C; Elsheikh TM
Diagn Cytopathol; 2012 May; 40(5):399-403. PubMed ID: 21681976
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Bethesda System for Reporting Thyroid Cytopathology in a Danish tertiary centre.
Madsen SH; Jespersen ML; Bonnema SJ; Rolighed L; Swan KZ
Dan Med J; 2024 May; 71(6):. PubMed ID: 38847411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
